X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
jCell (human retinal progenitor cells) is a first-in-class allogeneic cell therapy, which is being evaluated for the treatment of Retinitis Pigmentosa.
Lead Product(s): jCell
Therapeutic Area: Genetic Disease Product Name: jCell
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
Under the terms of the agreement, CBM will provide Phase 3 clinical trial supplies and commercial drug product following Biologics License Application (BLA) approval of jCyte’s proprietary jCell platform technology working on human retinal progenitor cells.
Lead Product(s): Human Retinal Progenitor Cells
Therapeutic Area: Genetic Disease Product Name: jCell
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Center for Breakthrough Medicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 20, 2022
Details:
David Liao, M.D., principal investigator of the Phase 2b study of jCell, presented data that demonstrated patients in target population, treated with a single 6 million cell dose, had an early, sustained, and significant mean improvement in best corrected visual acuity.
Lead Product(s): Human Retinal Progenitor Cells
Therapeutic Area: Genetic Disease Product Name: jCell
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: California Institute for Regenerative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2021
Details:
Phase 2b results show that treatment with jCell was well-tolerated and demonstrated encouraging evidence of potential benefit in patients as an investigational treatment for retinitis pigmentosa agnostic to genetic subtype.
Lead Product(s): Allogeneic human retinal progenitor cells
Therapeutic Area: Genetic Disease Product Name: jCell
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
Details:
Results from the Ph 2b trial of jCell in retinitis pigmentosa will be presented at the American Society of Retina Specialists. jCell is an investigational treatment for retinitis pigmentosa which has received FDA Regenerative Medicine Advanced Therapy designation.
Lead Product(s): Allogeneic human retinal progenitor cells
Therapeutic Area: Genetic Disease Product Name: jCell
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
Under the agreement, Santen Pharmaceutical will develop and commercialize its first-in-class, investigational therapy, jCell, outside the U.S., in regions including Europe, Asia and Japan.
Lead Product(s): jCell
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Santen Pharmaceutical
Deal Size: $252.0 million Upfront Cash: $50.0 million
Deal Type: Licensing Agreement May 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
